Market Research Report
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2017
|Published by||Global Markets Direct||Product code||410989|
|Published||Content info||39 Pages
|Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2017|
|Published: December 29, 2017||Content info: 39 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H2 2017, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.
Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 5 and 1 respectively.
Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.